Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Oramed Pharmaceuticals (ORMP) Leases (2019 - 2026)

Oramed Pharmaceuticals filings provide 7 years of Leases readings, the most recent being $750000.0 for Q4 2025.

  • Quarterly Leases rose 81.16% to $750000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $750000.0 through Dec 2025, up 81.16% year-over-year, with the annual reading at $750000.0 for FY2025, 81.16% up from the prior year.
  • Leases hit $750000.0 in Q4 2025 for Oramed Pharmaceuticals, down from $817000.0 in the prior quarter.
  • Across five years, Leases topped out at $1.1 million in Q1 2022 and bottomed at $342000.0 in Q1 2025.
  • Average Leases over 5 years is $723250.0, with a median of $722000.0 recorded in 2023.
  • The largest annual shift saw Leases soared 610.67% in 2021 before it tumbled 43.75% in 2025.
  • Oramed Pharmaceuticals' Leases stood at $504000.0 in 2021, then surged by 95.83% to $987000.0 in 2022, then dropped by 29.69% to $694000.0 in 2023, then tumbled by 40.35% to $414000.0 in 2024, then skyrocketed by 81.16% to $750000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Leases are $750000.0 (Q4 2025), $817000.0 (Q3 2025), and $882000.0 (Q2 2025).